Theravance Biopharma Inc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rick E. Winningham
- Full Time Employees
- 90
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 901 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- May 16, 2014
- CIK
- 0001583107
- Website
- theravance.com
- Similar Companies
- Business
- Theravance Biopharma, Inc. (TBPH) is a biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines for specialty respiratory and neurologic diseases. The company offers YUPELRI (revefenacin) inhalation solution, a once-daily nebulized long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in collaboration with Viatris Inc.; receives royalties from GlaxoSmithKline plc (GSK) on sales of TRELEGY Ellipta (fluticasone furoate/umeclidinium/vilanterol), a triple combination LABA/LAMA/ICS therapy for COPD and asthma; and advances ampreloxetine, a late-stage investigational once-daily norepinephrine reuptake inhibitor (NRI) for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Founded in 2014 and headquartered in South San Francisco, California, with additional operations in Dublin, Ireland, Theravance Biopharma targets patients in the United States and select international markets through strategic partnerships. Recent developments include the June 2025 sale of its remaining royalty interest in TRELEGY to GSK for $225 million to maximize shareholder value; Viatris' receipt of China National Medical Products Administration (NMPA) approval for YUPELRI in June 2025, triggering a $7.5 million milestone payment and potential sales-related milestones plus royalties; completion of enrollment in the pivotal Phase 3 CYPRESS study of ampreloxetine in MSA patients in August 2025, with topline data expected in Q1 2026 and plans for a new drug application submission; and strong YUPELRI demand growth of 6% year-over-year in Q3 2025 alongside Viatris collaboration revenue up 19%.
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Theravance Stock Down 3% After Zymeworks Announces Buyout
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks strikes $929 million deal for Theravance Biopharma
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock